Bronchoconstriction by nebulized metabisulfite solutions (SO2) and its modification by ipratropium bromide.
A nebulized solution of sodium metabisulfite (MBS) induced bronchoconstriction in nine subjects with asthma. An anticholinergic drug, ipratropium bromide (IPRA), in doses (500 to 700 micrograms) which were found to inhibit methacholine-induced bronchoconstriction, protected three of the nine subjects against nebulized MBS. These results suggest that both cholinergic and non-cholinergic reflex mechanisms are involved in MBS-induced bronchoconstriction.
Seale
J P
JP
Department of Pharmacology, University of Sydney, New South Wales, Australia.
Temple
D M
DM
Tennant
C M
CM
D001286:Atropine Derivatives / Q000494:pharmacology*; D001986:Bronchial Spasm / Q000139:chemically induced* / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005541:Forced Expiratory Volume; D006801:Humans; D009241:Ipratropium / Q000494:pharmacology*; D009330:Nebulizers and Vaporizers; D010366:Peak Expiratory Flow Rate; D012996:Solutions; D013447:Sulfites / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D001286:Atropine Derivatives; D012996:Solutions; D013447:Sulfites; C030981:metabisulfite; D009241:Ipratropium